Mark Scalzo
Papers
1
Total Citations
84
H-Index
1
About
Dr. Mark Scalzo is a leading urologic oncologist whose research focuses on the integration of novel theranostic agents in the surgical management of high-risk prostate cancer. His most impactful work centers on the perioperative administration of radioligand therapy, exemplified by the landmark "LuTectomy" study. As the lead author of this single-centre, Phase 1/2 trial (2023, 84 citations), Dr. Scalzo demonstrated the feasibility and safety of administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised disease. This pioneering contribution directly addresses a critical gap in treatment, exploring how targeted radiotherapy can be combined with surgery to improve oncologic outcomes. His work has been instrumental in advancing the concept of neoadjuvant theranostics, providing a foundation for larger, multi-centre trials. Dr. Scalzo’s research is widely recognized for its translational impact, bridging nuclear medicine and surgical oncology to redefine the therapeutic landscape for aggressive prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1